<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40779821</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>26</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1618-095X</ISSN><JournalIssue CitedMedium="Internet"><Volume>146</Volume><PubDate><Year>2025</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Phytomedicine : international journal of phytotherapy and phytopharmacology</Title><ISOAbbreviation>Phytomedicine</ISOAbbreviation></Journal><ArticleTitle>The Tanyu Tongzhi Formula enhances IL-10 expression and macrophage efferocytosis to alleviate atherosclerosis in mice.</ArticleTitle><Pagination><StartPage>157122</StartPage><MedlinePgn>157122</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.phymed.2025.157122</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0944-7113(25)00761-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Traditional Chinese Medicine (TCM), a significant subdiscipline within the realm of complementary medicine, has witnessed a surge in popularity across both Asian and Western nations over the past few decades. It holds potential as an adjunctive therapy for the management of atherosclerotic cardiovascular disease (ACVD). Tanyu Tongzhi Formula (TTF) -a TCM formula with decades of clinical application-has been demonstrated through completed randomized, controlled multicenter clinical studies to extend the maximum exercise duration in patients with chronic coronary syndrome and ameliorate TCM syndromes. TTF emerges as a promising therapeutic candidate for coronary artery disease characterized by phlegm stasis interaction. Additionally, TTF has demonstrated efficacy in protecting against atherosclerosis in murine models. However, the mechanisms by which TTF modulates macrophage function in atherosclerosis remain to be elucidated.</AbstractText><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To investigate IL-10-dependent efferocytosis regulation as a pivotal mechanism underlying TTF's modulation of macrophage function in atherosclerosis.</AbstractText><AbstractText Label="STUDY DESIGN AND METHODS" NlmCategory="METHODS">Low-density lipoprotein receptor or Apolipoprotein E null mice were subjected to a western diet for 8 weeks to induce atherosclerosis, after which they received TTF treatment for an additional 12 weeks. RNA sequencing was employed to identify interleukin-10 (IL-10) as a key downstream molecule. To verify the role of IL-10 in mediating the effects of TTF in reducing atherosclerosis, macrophage-specific IL-10 knockout mice were used.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">TTF administration significantly alleviated atherosclerosis in mice, evidenced by a reduction in atherosclerotic lesions and plaque necrosis, alongside an augmentation in collagen content. RNA sequencing revealed a substantial upregulation of IL-10 following TTF treatment, which corroborated in various macrophage populations and within mouse atherosclerotic plaques. IL-10 plays a crucial role in mediating the effects of TTF by enhancing macrophage efferocytosis. Notably, the targeted deletion of IL-10 in macrophages attenuated the therapeutic efficacy of TTF in mouse models of atherosclerosis. Furthermore, TTF activated the NF-&#x3ba;B pathway, leading to increased IL-10 expression. Trichosanthes kirilowii and Acorus tatarinowii were identified as the two functional components in TTF.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">IL-10-mediated efferocytosis potentiation is the critical pathway through which TTF stabilizes atherosclerotic plaques. The NF-&#x3ba;B/IL-10/efferocytosis axis provides a novel pharmacological target for macrophage-directed anti-atherosclerotic therapies. Tanyu Tongzhi Formula participates in the above regulatory mechanism and significantly alleviates atherosclerosis.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Authors. Published by Elsevier GmbH.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Chenxia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China; Department of Cardiology, Affiliated Zhejiang Hospital, Zhejiang University School of Medicine, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Tiantian</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lv</LastName><ForeName>Zhengtian</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Mingshuang</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Luoxia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kong</LastName><ForeName>Youjin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xinyi</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Affiliated Zhejiang Hospital, Zhejiang University School of Medicine, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rong</LastName><ForeName>Zheng</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Chenchen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Xinbin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Cardiology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Tingting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Zhejiang Key Laboratory of Integrative Chinese and Western Medicine for Diagnosis and Treatment of Circulatory Diseases, Hangzhou, China; Zhejiang Engineering Research Center for Precise Diagnosis and Innovative Traditional Chinese Medicine for Cardiovascular Diseases, Zhejiang Hospital (Affiliated Zhejiang Hospital, Zhejiang University School of Medicine), Hangzhou, Zhejiang 310007, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ju</LastName><ForeName>Zhenyu</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Key Laboratory of Regenerative Medicine of Ministry of Education, Institute of Aging and Regenerative Medicine, Jinan University, Guangzhou, China. Electronic address: zhenyuju@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Hongqiang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pathology and Pathophysiology and Department of Cardiology at Sir Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China. Electronic address: hqcheng11@zju.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Affiliated Zhejiang Hospital, Zhejiang University School of Medicine, Hangzhou, China; Zhejiang Key Laboratory of Integrative Chinese and Western Medicine for Diagnosis and Treatment of Circulatory Diseases, Hangzhou, China; Zhejiang Engineering Research Center for Precise Diagnosis and Innovative Traditional Chinese Medicine for Cardiovascular Diseases, Zhejiang Hospital (Affiliated Zhejiang Hospital, Zhejiang University School of Medicine), Hangzhou, Zhejiang 310007, China. Electronic address: maoweilw@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Phytomedicine</MedlineTA><NlmUniqueID>9438794</NlmUniqueID><ISSNLinking>0944-7113</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>130068-27-8</RegistryNumber><NameOfSubstance UI="D016753">Interleukin-10</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004365">Drugs, Chinese Herbal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C556062">IL10 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011973">Receptors, LDL</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016753" MajorTopicYN="Y">Interleukin-10</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050197" MajorTopicYN="Y">Atherosclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004365" MajorTopicYN="Y">Drugs, Chinese Herbal</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008264" MajorTopicYN="Y">Macrophages</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011973" MajorTopicYN="N">Receptors, LDL</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010587" MajorTopicYN="N">Phagocytosis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000097242" MajorTopicYN="N">Efferocytosis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Atherosclerosis</Keyword><Keyword MajorTopicYN="N">Efferocytosis</Keyword><Keyword MajorTopicYN="N">Il-10</Keyword><Keyword MajorTopicYN="N">Macrophage</Keyword><Keyword MajorTopicYN="N">Tanyu tongzhi formula</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>31</Day><Hour>20</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>8</Day><Hour>18</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>8</Day><Hour>18</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40779821</ArticleId><ArticleId IdType="doi">10.1016/j.phymed.2025.157122</ArticleId><ArticleId IdType="pii">S0944-7113(25)00761-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>